logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: News & Comments

From bluebird bio: FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy

FDA Approves bluebird bio Product Skysona for Early, Active CALD SKYSONA is the first FDA approved therapy shown to slow the progression of neurologic dysfunction in boys with this devastating and fatal neurodegenerative disease. The U.S. FDA has granted Accelerated...

Read More

September 19, 2022

0

Moderna COVID-19 Vaccine Produced Neutralizing Titers Against Key Emerging Variants Tested

Moderna COVID-19 Vaccination News A vaccination with the Moderna ( MRNA ) COVID-19 produced neutralizing titers against all key emerging variants tested, including B.1.1.7 and B.1.351, first identified in the UK and the Republic of South Africa, respectively. The study...

Read More

January 28, 2021

0

These Dangerous World Circumstances and the Prohost Portfolio

The circumstances that we find the world in today are abnormal. They are extremely intense and dangerous. We are living  an unprecedented, unexpected and inexplicable  war in Europe, which nobody seems to know how it would end up.  When it...

Read More

March 4, 2022

0

Intellia Therapeutics Statement on Recent U.S. Patent and Trademark Office Decision

Intellia Therapeutics Statement on Recent U.S. Patent and Trademark Office Decision - In May 2012, the Regents of University of California, University of Vienna, and Emmanuelle Charpentier (collectively, “CVC”) filed a patent application for their CRISPR/Cas9 genome editing technology. The...

Read More

March 4, 2022

0

Researchers at the Children’s Hospital of Philadelphia are Improving Gene Therapy Vectors

The Children's Hospital of Philadelphia: Improving Gene Therapy Vectors Improving gene therapy vectors seems to have come at the hands of researchers at Children’s Hospital of Philadelphia ( CHOP ). A gene therapy vector was developed for blood disorders like...

Read More

February 5, 2021

0

Vir Biotechnology and GlaxoSmithKline Expanded Agreement

Vir Biotechnology and GlaxoSmithKline Expanded Collaboration  Vir Biotechnology ( VIR ) and GlaxoSmithKline plc ( GSK ) announced the signing of a binding agreement to expand their existing collaboration to include the research and development of new therapies for influenza...

Read More

February 17, 2021

0

Novavax is Bringing its COVID-19 Vaccine to the World’s Markets

Novavax Inc The Novavax ( NVAX ) COVID-19 Vaccine NVX-CoV2373 is on its way to reaching worldwide markets.  The Serum Institute of India ( SII ) and the Vaccine Alliance ( Gavi ) are to ensure equitable access to Novavax's, NVX-CoV2373, vaccine...

Read More

February 19, 2021

0

Reata Pharmaceuticals Completed Rolling NDA Submission of Omaveloxolone for Friedreich’s Ataxia

Reata Pharmaceuticals Completed Rolling NDA Submission for Omaveloxolone for Friedreich's Ataxia Reata Pharmaceuticals ( RETA ) announced the completion of the rolling submission of a New Drug Application ( NDA ) to the U.S. FDA for omaveloxolone’s treatment of Friedreich’s...

Read More

April 1, 2022

0

Cassava Sciences: Good News During Bad Market Days

The market is sinking in a furious mood caused by the failure to figure out the pathway of criteria, which is currently controlling the stocks’ volatile performances. Today we are posting good news coming from a few biotech companies with...

Read More

February 23, 2021

0

Sunshine Biopharma's New mRNA Therapeutics Killed Cancer Cells with Little or No Adverse Effects

Sunshine Biopharma mRNA Therapeutics Effective at Destroying Cancer Cells Sunshine Biopharma, Inc. ( SBFM ) -  a pharmaceutical company focused on research, development and commercialization of oncology and antiviral drugs, announced that two of its newly designed mRNA molecules are...

Read More

April 5, 2022

0

  • Previous
  • 1
  • 2
  • ...
  • 102
  • 103
  • 104
  • ...
  • 115
  • 116
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy